Merck (NYSE:MRK) announced late-stage trial data on Thursday suggesting that its Capvaxive vaccine, indicated for adults to prevent invasive pneumococcal disease and pneumonia, is also effective in those aged 2–18 years. Citing a 30-day post-vaccination analysis from its Phase 3 ...